Related Experiment Videos
[Mezlocillin: tissue concentration and efficacy (author's transl)]
Medizinische Klinik
|January 26, 1979
Summary
Mezlocillin, a new penicillin antibiotic, showed good tissue distribution and was effective in treating severe infections, with high cure rates and good tolerance in patients.
Area of Science:
- Pharmacology
- Microbiology
- Clinical Medicine
Context:
- Mezlocillin (Baypen) is a novel semi-synthetic acyl ureidopenicillin.
- Previous studies have investigated its pharmacokinetic and pharmacodynamic properties.
Purpose:
- To evaluate serum and tissue concentrations of mezlocillin.
- To assess the efficacy and tolerance of mezlocillin in treating severe infections.
Summary:
- Serum half-life was 59 minutes, with highest concentrations in skin (cutis) and lowest in muscles; liver concentrations were persistent.
- In 48 patients with 56 severe infections, mezlocillin (5g BID/TID) achieved a 78.5% clinical cure rate, with 76% microbial elimination.
- Indications included bronchopulmonary, peritonitis, soft tissue, biliary, and urinary tract infections, and postoperative fever.
Impact:
- Mezlocillin demonstrates favorable pharmacokinetic profiles and significant clinical efficacy in managing a range of severe bacterial infections.
- The antibiotic was well-tolerated both locally and systemically, suggesting a good safety profile for clinical use.